Abstract

PIP: 43 women aged 21-35 with 0-4 parity wearing Lippes Loop IUD were studied in a double-blind trail during 3 menstrual cycles to find out if proquazon, a prostaglandin (PG) synthesis inhibitor, prevented the adverse effects of the IUD. IUDs increase the PG level in the endometrium. Higher PG levels result in pain through uterine cramping and endometrial bleeding caused by increased vascular permeability (70- 10-0 ml. blood loss vs. the normal amount of 35 ml). 200 mg of proquazon was administered 3/day (t.i.d.) for 79 cycles and 1 capsule of placebo was given for 50 cycles. Proquazon mitigated pain and reduced the incidence of severe pain: pain was absent in 33 (42% cycles with proquazon vs. 7 (14%) with placebo; light pain occurred in 29 (37%) vs. 15 (30%) respectively; medium strong pain occurred in 12 (15%) vs. 17 (34%), respectively; and severe pain was observed in 5 (6.3%) vs. 11 (22%), respectively.